

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau

(43) International Publication Date
21 July 2022 (21.07.2022)



(10) International Publication Number
WO 2022/155258 A1

(51) International Patent Classification:

A61K 39/12 (2006.01) C07K 14/005 (2006.01)
A61P 31/18 (2006.01) C07K 19/00 (2006.01)

(21) International Application Number:

PCT/US2022/012195

(22) International Filing Date:

12 January 2022 (12.01.2022)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

63/137,521	14 January 2021 (14.01.2021)	US
63/149,820	16 February 2021 (16.02.2021)	US
63/170,900	05 April 2021 (05.04.2021)	US

(71) Applicant: **GILEAD SCIENCES, INC.** [US/US]; 333 Lakeside Drive, Foster City, California 94404 (US).

(72) Inventors: **LI, Jiani**; c/o Gilead Sciences, Inc., 333 Lakeside Drive, Foster City, California 94404 (US). **LIU, Xi-nan**; Room B155, No. 208 Juli Road, Pudong New District, Shanghai, Shanghai 101210 (CN). **MAKADZANGE, Azure T.**; 130 El Granada Boulevard, Half Moon Bay, California 94019 (US). **MARTIN, Stephen R.**; c/o Gilead Sciences, Inc., 333 Lakeside Drive, Foster City, California 94404 (US). **SCHMIDT, Sarah**; c/o Hookipa Biotech

GmbH, Helmut-Qualtinger-Gasse 2, 1030 Vienna (AT). **SHEHATA, Hesham**; 1000 Escalon Avenue, Apt. L1092, Sunnyvale, California 94085 (US). **STEMESEDER, Felix**; c/o Hookipa Biotech GmbH, Helmut-Qualtinger-Gasse 2, 1030 Vienna (AT). **SVAROVSKAIA, Evguenia**; c/o Gilead Sciences, Inc., 333 Lakeside Drive, Foster City, California 94404 (US). **BOOPATHY, Archana V.**; c/o Gilead Sciences, Inc., 333 Lakeside Drive, Foster City, California 94404 (US).

(74) Agent: **WAHLSTEN, Jennifer L.** et al.; Gilead Sciences, Inc., 333 Lakeside Drive, Foster City, California 94404 (US).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, IT, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH,

(54) Title: HIV VACCINES AND METHODS OF USING




FIG. 1

(57) Abstract: Provided are HIV-1 fusion polypeptides, polynucleotides encoding such fusion polypeptides, vectors expressing such fusion polypeptides for use in eliciting an immune response against HIV-1; pharmaceutical and immunogenic compositions and kits comprising such fusion polypeptides, polynucleotides or vectors, and methods of use in treating and/or preventing HIV-1. Further provided are methods for design of antiviral vaccines, including vaccines to elicit an immune response against HIV-1.

[Continued on next page]

GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

- *as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))*
- *as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii))*

Published:

- *with international search report (Art. 21(3))*
- *before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))*
- *with sequence listing part of description (Rule 5.2(a))*